Premium
Pharmacokinetics of enrofloxacin in snakehead fish, Channa argus
Author(s) -
Fang X.,
Zhou J.,
Liu X.
Publication year - 2016
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12262
Subject(s) - enrofloxacin , pharmacokinetics , snakehead , cmax , chemistry , metabolite , bioavailability , active metabolite , oral administration , florfenicol , high performance liquid chromatography , zoology , fish <actinopterygii> , pharmacology , chromatography , ciprofloxacin , fishery , biology , antibiotics , biochemistry
The pharmacokinetics of enrofloxacin (EF) was investigated after single intravenous (i.v.) and oral (p.o.) dose of 10 mg/kg body weight (b.w.) in snakehead fish at 24–26 °C. The plasma concentrations of EF and its metabolite ciprofloxacin (CF) were determined by high‐performance liquid chromatography. The plasma concentration–time data were described by an open two‐compartment model for both routes. After intravenous administration, the elimination half‐life ( T 1/2β ), area under the concentration–time curve (AUC) and total body clearance of EF were 19.82 h, 75.79 μg h/mL and 0.13 L/h/kg, respectively. Following p.o. administration, the maximum plasma concentration ( C max ), T 1/2β and AUC of EF were 1.86 μg/mL, 35.8 h and 49.98 μg h/mL, respectively. Absorption of EF was good with a bioavailability ( F ) of 65.82%, which was higher than that calculated in most seawater fish. CF, an active metabolite of EF, was detected occasionally in this study, which indicates a low extent of deethylation of EF in snakehead fish.